Company / Working Capital per Share
Viridian Therapeutics, Inc.\DE Working Capital per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital per Share
$8.53
FY2024
5-year range
$8.53 / $15.65
FY2020-FY2024
Trend
-17.0%
vs FY2023
Sector context
#59 of 210
Health Care
What the data says
At $8.53, Viridian Therapeutics, Inc.\DE's working capital per share ranks #59 of 210 in the Health Care sector. Working Capital per Share has declined for 4 consecutive years, from $33.44 in FY2020 to $8.53 in FY2024.
Based on SEC 10-K filings.
8.53 in FY2024 with a 5-year CAGR of -1.9%.
Declined from $12.40 to $8.53 over the past 2 years.
Health Care sector context is included.
Working Capital per Share over time
Growth rates
- 3-Year CAGR
- -18.3%
- 5-Year CAGR
- -1.9%
- 10-Year CAGR
- -
Sector benchmark
#59 of 210 in Health CareTop 28% of 210This company $8.53 Sector average $146.86
▼
-94.2% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's working capital per share has declined for 4 consecutive years.
- In FY2024, working capital per share decreased 17.0% year-over-year.
- Ranks #59 out of 210 companies in the Health Care sector.
- Peak working capital per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working Capital per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $8.53 | -17.0% |
| FY2023 | $10.27 | -17.1% |
| FY2022 | $12.40 | -20.8% |
| FY2021 | $15.65 | -53.2% |
| FY2020 | $33.44 | +257.1% |
| FY2019 | $9.36 | +372.6% |
| FY2018 | $1.98 | -96.6% |
| FY2017 | $57.54 | +140.1% |
| FY2016 | $23.97 | +878.3% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026